Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
A multicentric, open-label, single-arm prospective study to assess the efficacy and safety of
tislelizumab combined with TACE as first-line treatment in patients with unresectable BCLC
stage C HCC.